Share this article on:

Interleukin 1β and Interleukin 1 Receptor Antagonist Gene Polymorphisms and Cervical Cancer: A Meta-analysis

Wu, Shimu MD*; Hu, Guiping MD; Chen, Jun MD*; Xie, Guangyun MD

International Journal of Gynecological Cancer: July 2014 - Volume 24 - Issue 6 - p 984–990
doi: 10.1097/IGC.0000000000000165
Basic Science

Objectives Previous studies investigating the association between interleukin 1β (IL-1β) and its receptor antagonist (IL-1RN) polymorphism and cervical cancer risk have reported controversial results. Thus, we examined these associations by performing meta-analyses.

Methods and Materials Fourteen studies testing the association between IL-1β and/or IL-1RN gene polymorphisms and cervical cancer were examined: 5 studies of IL-1β–511C/T, 3 studies of IL-1β–31T/C, and 6 studies of IL-1RN. Overall and ethnicity-specific summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for cervical cancer associated with these polymorphisms were estimated using fixed- and random-effects models. Heterogeneity and publication bias were evaluated.

Results Meta-analysis of all 6 studies showed variant genotypes of IL-1RN to be associated with an elevated cervical cancer risk (RN2/RN2 vs RN1/RN1: OR, 2.64; 95% CI, 1.29–5.40; recessive: OR, 2.15; 95% CI, 1.06–4.38; dominant: OR, 1.60; 95% CI, 1.07–2.38). Combined analysis indicated that IL-1β–511C/T polymorphism was also associated with increased risk of cervical cancer (TT vs CC: OR, 1.56; 95% CI, 1.22–1.99; CT vs CC: OR, 1.61; 95% CI, 1.31–1.99; dominant: OR, 1.60; 95% CI, 1.31–1.95). No significant association of IL-1β–31T/C and cervical cancer risk was detected. There was no evidence of publication bias.

Conclusions This meta-analysis suggested that the IL-1RN and IL-1β–511C/T polymorphisms may contribute to genetic susceptibility of cervical cancer. More studies are needed to further evaluate the role of the IL-1β–31T/C polymorphism in the etiology of cancer.

Departments of *Laboratory Medicine, †Anesthesiology, and ‡Nursing, The People’s Hospital of Xingyi, Xingyi City, Guizhou, China.

Address correspondence and reprint requests to Shimu Wu, MD, Department of Laboratory Medicine, The People’s Hospital of Xingyi, No. 1, Yuanlin Rd, Xingyi City, Guizhou 562400, China. E-mail:

The authors declare no conflicts of interest.

Received February 21, 2014

Accepted April 1, 2014

© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.